Circle Pharma, a San Francisco, CA-based clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, raised $90M in Series D funding.
The round was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital.
The company intends to use the funds to fund the clinical development of CID-078, its cyclin A/B RxL inhibitor, and to support the development of its portfolio of discovery programs built with its MXMO macrocycle platform.
Led by CEO David Earp, Circle Pharma discovers and develops cell-permeable macrocycles that can be delivered by multiple routes, including oral administration. Its MXMO™ platform combines structure-based rational drug design and advanced synthetic chemistry to develop new macrocycle therapies for challenging targets to address unmet clinical needs.
Commenting on the news, David Earp said: “This financing not only enables us to progress CID-078 through critical stages of clinical development but also allows us to further advance our pipeline of innovative therapies targeting cancer and other serious diseases.”
FinSMEs
03/09/2024